Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's decision to deny Genentech fast-track status for Lucentis (ranibizumab) means that the initial submission for the wet age-related macular degeneration therapy, slated for December, will not include data supporting a dosing advantageYou may also be interested in...
Retaane “Approvable” For Macular Degeneration; Alcon Plans July Meeting With FDA
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: